MBD2 and breast cancer: Although these assays were not quantitative enough to monitor potential changes in MBD2 deposition by ChIPseq, ChIP assays indicated that CAF-CMs can reduce MBD2 deposition at several upregulated genes, in SKBR3 and AU565 breast cancer cell lines.